NASDAQ: PRME
Prime Medicine Inc Stock Ownership - Who owns Prime Medicine?

Insider buying vs selling

Have Prime Medicine Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Arch Venture Partners XII LLC10% Owner2025-08-013,030,300$3.30
$10.00MBuy
Arch Venture Partners X LLC10% Owner2025-08-013,030,300$3.30
$10.00MBuy
Gv 2021 GP LLC10% Owner2025-08-011,500,000$3.30
$4.95MBuy
Robert NelsenDirector2025-08-013,030,300$3.30
$10.00MBuy

1 of 1

PRME insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRME insiders and whales buy or sell their stock.

PRME Shareholders

What type of owners hold Prime Medicine Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
David R. Liu11.21%20,240,945$63.35MInsider
Robert Nelsen10.24%18,502,974$57.91MInsider
Arch Venture Partners X LLC10.24%18,486,894$57.86MInsider
Arch Venture Partners XII LLC10.24%18,486,894$57.86MInsider
Alphabet Inc9.17%16,562,498$51.84MInstitution
Gv 2019 GP LLC6.57%11,862,498$37.13MInsider
Blackrock Inc4.71%8,501,708$26.61MInstitution
Fmr LLC4.69%8,462,946$26.49MInsider
State Street Corp3.51%6,345,125$19.86MInstitution
Ark Investment Management LLC3.46%6,246,827$19.55MInstitution

1 of 3

PRME vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRME46.23%53.77%Net Buying
ALT35.67%32.64%Net Buying
IMMX49.76%17.93%Net Buying
FDMT80.12%19.88%Net SellingNet Selling
STTK73.12%19.69%Net BuyingNet Buying

Prime Medicine Stock Ownership FAQ

Who owns Prime Medicine?

Prime Medicine (NASDAQ: PRME) is owned by 54.57% institutional shareholders, 63.48% Prime Medicine insiders, and 0.00% retail investors. David R. Liu is the largest individual Prime Medicine shareholder, owning 20.24M shares representing 11.21% of the company. David R. Liu's Prime Medicine shares are currently valued at $63.35M.

If you're new to stock investing, here's how to buy Prime Medicine stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.